Welcome to our dedicated page for GRAY news (Ticker: GRAY), a resource for investors and traders seeking the latest updates and insights on GRAY stock.
The GRAY news archive on Stock Titan covers the historical public communications of Graybug Vision, Inc., which previously traded on Nasdaq under the symbol GRAY. Company press releases describe Graybug as a clinical-stage biopharmaceutical company focused on developing medicines for ocular diseases, including vision-threatening disorders of the retina, optic nerve, and cornea.
News items in this archive include updates on Graybug’s investigational pipeline, such as GB-102 for wet age-related macular degeneration, GB-401 for primary open-angle glaucoma, and gene therapy and sustained-release candidates like GB-501, GB-601, and GB-701. Releases also document participation in ophthalmology conferences and scientific meetings where the company presented preclinical and clinical data related to its programs.
Another important theme in the GRAY news history is corporate strategy. Graybug announced a review of strategic alternatives, outlining potential options such as a merger or company sale, followed by cost-containment measures and changes to its development activities. Subsequent news detailed a definitive merger agreement with CalciMedica Inc., an all-stock transaction intended to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on life-threatening inflammatory diseases.
The archive further records the name and trading symbol change from Graybug Vision, Inc. (GRAY) to CalciMedica, Inc. (CALC) on the Nasdaq Global Market, undertaken in connection with the merger. Readers using this page can follow the historical progression from Graybug’s focus on ophthalmology through its strategic review and combination with CalciMedica. For ongoing developments after the name and ticker change, company communications direct attention to CalciMedica, Inc. under the symbol CALC.
Investors and researchers can use this GRAY news collection as a historical reference to understand Graybug’s former pipeline, its clinical and preclinical milestones, and the sequence of events leading to its merger and rebranding as CalciMedica, Inc.
BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, a clinical-stage biopharmaceutical company, announced CEO Fred Guerard's participation at the Ophthalmology Innovation Summit (OIS) Retina on October 7, 2021, in San Antonio, Texas. He will present at the "Innovation Showcase" at 11:05 a.m. ET and participate in the "Finding and Funding Assets in Retina" panel at 4:55 p.m. ET. Graybug focuses on transformative medicines for retinal diseases, with its lead candidate, GB-102, targeting prolonged dosing regimens to improve treatment outcomes.
Graybug Vision, Inc. (Nasdaq: GRAY) announced favorable results from the 18-month Phase 2b ALTISSIMO trial for GB-102, targeting wet AMD. Key findings include 55% of patients in the Extension Study achieving treatment durations of 12 months or more, with maintained visual acuity. The trial also demonstrated a 73% reduction in injection burden, and GB-102 maintained a favorable safety profile with no adverse events reported. The company is exploring further development opportunities for GB-102 and anticipates starting a Phase 1 trial for GB-401 in late 2022.
Graybug Vision (Nasdaq: GRAY) announced that CEO Fred Guerard will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 11:20 a.m. ET. The presentation will include a corporate update and an analysis of the 18-month data from the ALTISSIMO Phase 2b trial of GB-102 1mg. A live webcast will be accessible via the company’s website, with a replay available post-event. Graybug focuses on innovative treatments for retinal and optic nerve diseases, utilizing advanced ocular delivery technologies designed for prolonged drug effectiveness.
Graybug Vision, Inc. (Nasdaq: GRAY) reported its financial results for the quarter and six months ending June 30, 2021. The company incurred a net loss of $7.7 million for the quarter and $19.2 million for the six-month period, showing increases from $5.9 million and $13.7 million respectively in 2020. Research and development expenses decreased slightly at $10.6 million, while general and administrative expenses rose to $8.6 million, primarily due to increased stock-based compensation and insurance costs. The company’s cash position stands at $78.2 million, projected to fund operations into 2023.
Graybug Vision, a clinical-stage biopharmaceutical company specializing in retinal and optic nerve diseases, announced that its CEO, Fred Guerard, will participate in the "Goldeneye" panel at the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 9:45 a.m. ET. The event will be webcast live, with a replay available for 14 days thereafter. Graybug’s innovative delivery technologies allow for sustained drug release, improving treatment for conditions like wet age-related macular degeneration and glaucoma. For further details, visit their website.
Graybug Vision, a clinical-stage biopharmaceutical company, reported financial results for Q1 2021. The net loss increased to $11.4 million from $7.8 million in Q1 2020. R&D expenses rose to $6.4 million, influenced by clinical supply order cancellations for GB-102's Phase 3 trial. General and administrative expenses surged to $5.0 million due to fixed asset write-offs and increased headcount. As of March 31, 2021, cash and investments totaled $85.7 million, down from $95.0 million at year-end 2020, yet sufficient to fund operations into H1 2023. The company is advancing trials for GB-102 and GB-401.
Graybug Vision (NASDAQ: GRAY) has provided a full-data analysis from the Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration, demonstrating competitive durability and anatomical control compared to aflibercept.
Despite a trend of lower mean best-corrected visual acuity (BCVA) for GB-102, the treatment was safe and well-tolerated with no serious drug-related adverse events. The company plans to explore enhanced formulations of GB-102 and continue the development of its GB-401 implant for glaucoma. Current cash reserves are sufficient to support operations into 2023.
Graybug Vision, Inc. (Nasdaq: GRAY) announced a conference call on May 12, 2021, to discuss the full-data analysis of the 12-month treatment phase of its Phase 2b ALTISSIMO trial. The call will occur at 8 a.m. ET and will be accessible via phone or webcast. Graybug focuses on innovative treatments for retinal and optic nerve diseases, with its lead product candidate, GB-102, aiming for longer dosing regimens. The company also develops GB-401 for glaucoma and GB-103 for retinal tissue maintenance.
Graybug Vision (NASDAQ: GRAY) announced preliminary results from its Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration. The median time to first supportive therapy was 5 months for the 1 mg dose, with 48% of patients remaining rescue-free for over 6 months. The drug demonstrated consistent retinal thickness control, although mean best-corrected visual acuity was lower compared to the aflibercept control group. Importantly, there were no drug-related serious adverse events reported. The next steps will be determined following a full analysis of the trial results.
Graybug Vision, Inc. (Nasdaq: GRAY) reported a net loss of $27.5 million for the year ended December 31, 2020, a decrease from $37.0 million in 2019. Key highlights include the completion of the 12-month treatment phase of the ALTISSIMO trial for GB-102 in wet AMD, with topline data expected in March 2021. The company's cash and investments reached $95.0 million, largely due to a successful IPO, supporting operations into Q1 2022. Graybug is set to initiate pivotal Phase 3 trials and a Phase 2b trial for GB-102 and plans to submit an IND for a new product, GB-401, in 2021.